A current state of mycobacterioses

Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(4):276-282

​ Zimina V.N., Degtyaryova S.Yu., Beloborodova E.N., Kulabukhova E.I., Rusakova L.I., Fesenko O.V.
non-tuberculous mycobacteria mycobacteriosis drug susceptibility test chemotherapy
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(4):276-282

Abstract

Mycobacterioses are caused by multiple opportunistic bacteria that are ubiquitous. The incidence rate of nontuberculosis mycobacterial infections (NTM) is rising due to an increased number of immunocompromised patients and advances in diagnosis. Different medical specialties deal with mycobacterioses: pulmonologists, phtisiologists, infectious diseases specialists, pediatricians, dermatovenereologists, orthopedists, surgeons. There is a lot of unknown issues concerning mycobacterioses treatment; international guidelines on the treatment of NTM do not have a high level of evidence; and national guidelines on the management of patients with NTM are lacking. This review focuses on the classification, epidemiology, and diagnosis of pulmonary NTM. The interpretation of drug susceptibility testing (DST) results for clinical decision-making process, treatment regimens and duration for different species of NTM as well as further medical treatment perspectives are also detailed in this article.

Vera N. Zimina

RUDN University, Moscow, Russia

Degtyaryova S.Yu.

RUDN University, Moscow, Russia

Beloborodova E.N.

RUDN University, Moscow, Russia

Kulabukhova E.I.

Central Research Institute of Epidemiology, Moscow, Russia

Rusakova L.I.

Central Research Institute of Tuberculosis, Moscow, Russia

Fesenko O.V.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

  • 1. Timpe A., Runyon E.H. The relationship of «atypical» acid-fast bacteria to human disease; a preliminary report. J Lab Clin Med. 1954;(2):202-209.
  • 2. Prevots D.R., Loddenkemper R., Sotgiu G., Migliori G.B. Nontuberculous mycobacterial burden with substantial costs. Eur Respir J. 2017; 49(4). pii: 1700374.
  • 3. Winthrop K.L., Baxter R., Liu L., et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72(1):37-42.
  • 4. Andréjak C., Nielsen R., Thomsen V., et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256-262.
  • 5. Salsgiver E.L., Fink A.K., Knapp E.A., et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest. 2016;149(2):390-400.
  • 6. Brode S.K., Daley C.L., Marras T.K. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc lung Dis. 2014;18(11):1370-1377.
  • 7. Strollo S.E., Adjemian J., Adjemian M.K., Prevots D.R. The burden of pulmonary nontuberculous mycobacterial disease in the United States. Ann Am Thorac Soc. 2015;12(10):1458-1464.
  • 8. Jarand J., Levin A., Zhang L., et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011;52(5):565-571.
  • 9. van Ingen J., Bendien S.A., de Lange W.C.M., et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, the Netherlands. Thorax. 2009;64(6):502-506.
  • 10. Griffith D.E., Aksamit T., Brown-Elliott B.A., et al. An official ATS/ IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416.
  • 11. Van Ingen J., Wagner D., Gallagher J., et al. Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. Eur Respir J. 2017;49(2):10-13.
  • 12. Adjemian J., Prevots D.R., Gallagher J., et al. Lack of adherence to evidencebased treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11(1):9-16.
  • 13. Panteleev A.M., Dracheva M.S., Nikulina O.V., Sokolova O.S., Zonova A.V. Clinical and laboratory features of atypical mycobacteriosis in HIV-patients. Zhurnal infektologii. 2016;8(3):40-45. Russian.
  • 14. Guntupova L.D., Borisov S.E., Solovyeva I.P., Makarova M.V., Hachaturyants E.N. Mycobacteriosis in phtisiopulmonologic practice: an overview of literature and own experience. Prakticheskaja medicina. 2011;3(51):39-50. Russian.
  • 15. Ergeshov A.E., Shmelev E.I., Kovalevskaya M.N., et al. Mycobacteriosis in the practice of pulmonologists and phthisiologists. Tuberkulez i bolezni legkih. 2016;94(9):39-43. Russian.
  • 16. Federal Budget Institution of Science "Central Research Institute of Epidemiology", Federal Scientific and Guidance Centre for AIDS Prevention and Treatment. National recommendations for dispensary observation and treatment of HIV patients (clinical protocol); 2016. Russian.
  • 17. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clin Microbiol Infect. 2009;15(10):906-910.
  • 18. List of prokaryotic names with standing in nomenclature [Internet]. [Accessed 2017 Sep 13]. Available at: www.bacterio.net/-classifphyla.html.
  • 19. Heifets L. Infections caused by nontuberculous mycobacteria. Semin Respir Crit Care Med. 2004;25(3):283-295.
  • 20. Supplement №1 СП 1.3.2322-08 Safety of work with microorganisms of III-IV groups of pathogenicity; 2008. Russian.
  • 21. Falkinham J.O. Ecology of nontuberculous mycobacteria – where do human infections come from? Semin Respir Crit Care Med. 2013;34:95-102.
  • 22. Astagneau P., Desplaces N., Vincent V., et al. Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet. 2001;358(9283):747-751.
  • 23. Kohler P., Kuster S.P., Bloemberg G., et al. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery. Eur Heart J. 2015;36(40):27452753.
  • 24. Bryant J.M., Grogono D.M., Greaves D., et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013;381(9877):15511560.
  • 25. Eckburg P.B., Buadu E.O., Stark P., et al. Clinical and chest radiographic findings among persons with sputum culture positive for Mycobacterium gordonae: A review of 19 cases. Chest. 2000;117(1):96-102.
  • 26. Stout J.E., Koh W.J., Yew W.W. Update on pulmonary disease due to nontuberculous mycobacteria. Int J Infect Dis. 2016;45:123-134.
  • 27. Otten T.F., Vasil'ev A.V. Mycobacteriosis. SPb: Medicinskaja pressa; 2005. 224 p. Russian.
  • 28. Hoefsloot W., Van Ingen J., Andrejak C., et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: An NTMNET collaborative study. Eur Respir J. 2013;42(6):1604-1613.
  • 29. Sniadack D.H., Ostroff S.M., Karlix M.A., et al. A nosocomial pseudooutbreak of Mycobacterium xenopi due to a contaminated potable water supply: lessons in prevention. Infect Control Hosp Epidemiol. 1993;14(11):636-641.
  • 30. Jenkins P.A., Campbell I., Banks J., et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008;63(7):627-634.
  • 31. Lambert P.A. Cellular impermeability and uptake of biocides and antibiotics in gram-positive bacteria and mycobacteria. J Appl Microbiol Symp Suppl. 2002;92:46-54.
  • 32. Tanaka E., Kimoto T., Tsuyuguchi K., et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. 1999;160:866-872.
  • 33. Woods G.L., Brown-Elliott B.A., Conville P.S., et al. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; Approved Standard – Second Edition. 2011. 1-61 p.
  • 34. Chernousova L.N., Sevastjanova Je.V., Larionova E.E., Smirnova T.G., Andreevskaja S.N, Popov S.A. Federal clinical guidelines for the organization and conduct of microbiological and molecular genetic diagnosis of tuberculosis. Tver: OOO "Izdatelstvo Triada"; 2015. 46 p. Russian.
  • 35. Research Commitee of the BTS. First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax. 2001;56(3):167-172.
  • 36. Conte J.E., Golden J., Duncan S., et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother. 1996;40(7):1617-1622.
  • 37. Wallace R.J., Brown-Elliott B.A., McNulty S., et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014;146(2):276-282.
  • 38. Ward T.T., Rimland D., Kauffman C., Huycke M., Evans T.G. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Clin Infect Dis. 1998;27(5):1278-1285.
  • 39. Wallace R.J., Brown B.A., Griffith D.E., Girard W.M., Murphy D.T. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996;153(6):1766-1772.
  • 40. Kobashi Y., Yoshida K., Miyashita N., Niki Y., Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother. 2006;12(4):195-202.
  • 41. Brown-Elliott B.A., Iakhiaeva E., Griffith D.E., et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013;51(10):3389-3394.
  • 42. Van Ingen J., Egelund E.F., Levin A., et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186(6):559-565.
  • 43. Аndreevskaya S.N., Larionova E.E., Smirnova T.G., Аndrievskaya I.Y., Kiseleva E.A., Chernousova L.N. Drug susceptibility of low growing nontuberculous mycobacteria. Tuberculosis and Lung Diseases. Tuberkulez i bolezni legkih. 2016;94(4):43-50. Russian.
  • 44. Hoffner S.E., Svenson S.B., Beezer A.E. Microcalorimetric studies of the initial interaction between antimycobacterial drugs and Mycobacterium avium. J Antimicrob Chemother. 1990;25(3):353-359.
  • 45. Nannini E.C., Keating M., Binstock P., Samonis G., Kontoyiannis D.P. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J Infect. 2002;44(3):201-203.
  • 46. Griffith D.E., Brown-Elliott B.A., Langsjoen B., et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174(8):928-934.
  • 47. Wallace R.J.J., Zhang Y., Dawson D., et al. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med. 1998;158(4):1235-1244.
  • 48. Griffith D.E., Brown-Elliott B.A., Wallace Richard J.J. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis. 2003;37(9):11781182.
  • 49. Ahn C.H., Lowell J.R., Ahn S.S., Ahn S., Hurst A.G. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis. 1981;3(5):1028-1034.
  • 50. Wallace R.J.J., Dunbar D., Brown B., et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis. 1994;18(5):736-743.
  • 51. Andréjak C., Almeida D.V., Tyagi S., et al. Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. J Antimicrob Chemother. 2013;68(3):659-665.
  • 52. Andréjak C., Lescure F.X., Pukenyte E., et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in northeast France. Thorax. 2009;64(4):291-296.
  • 53. Floto R.A., Olivier K.N., Saiman L., et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71:i1-i22.
  • 54. Jeon K., Kwom O.J., Lee N.Y., et al. Antibiotic treatment of Mycobacterium abscessus lung disease. Am J Respir Crit Care Med. 2009;180(9):896-902.
  • 55. Ferro B.E., Van Ingen J., Wattenberg M., Van Soolingen D., Mouton J.W. Time-kill kinetics of antibiotics active against rapidly growing mycobacteria. J Antimicrob Chemother. 2015;70(3):811-817.
  • 56. Choi G.E., Shin S.J., Won C.J., et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012;186(9):917-925.
  • 57. Mitchell J.D. Surgical approach to pulmonary nontuberculous mycobacterial infections. Clin Chest Med. 2015;36(1):117-122.
  • 58. Olivier K.N., Griffith D.E., Eagle G., et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2016;195(6):814-823.
  • 59. Van Ingen J., Totten S.E., Helstrom N.K., et al. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012;56(12):6324-6327.
  • 60. Philley J.V., Wallace R.J., Benwill J.L., et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest. 2015;148(2):499-506.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared